-
Kenya's economy faces climate change risks: World Bank
-
Stocks, dollar rise before key US inflation data
-
After wins abroad, Syria leader must gain trust at home
-
Markets rise ahead of US data, expected Fed rate cut
-
German factory orders rise more than expected
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Georgia's street dogs stir affection, fear, national debate
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Pentagon endorses Australia submarine pact
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
OpenAI strikes deal on US$4.6 bn AI centre in Australia
-
Rains hamper Sri Lanka cleanup after deadly floods
-
Unchecked mining waste taints DR Congo communities
-
Asian markets mixed ahead of US data, expected Fed rate cut
-
French almond makers revive traditions to counter US dominance
-
Aid cuts causing 'tragic' rise in child deaths, Bill Gates tells AFP
-
Abortion in Afghanistan: 'My mother crushed my stomach with a stone'
-
Mixed day for US equities as Japan's Nikkei rallies
-
To counter climate denial, UN scientists must be 'clear' about human role: IPCC chief
-
Facebook 'supreme court' admits 'frustrations' in 5 years of work
-
South Africa says wants equal treatment, after US G20 exclusion
-
One in three French Muslims say suffer discrimination: report
-
Microsoft faces complaint in EU over Israeli surveillance data
-
Milan-Cortina organisers rush to ready venues as Olympic flame arrives in Italy
-
Truth commission urges Finland to rectify Sami injustices
-
Stocks rise eyeing series of US rate cuts
-
Italy sweatshop probe snares more luxury brands
-
EU hits Meta with antitrust probe over WhatsApp AI features
-
Russia's Putin heads to India for defence, trade talks
-
South Africa telecoms giant Vodacom to take control of Kenya's Safaricom
-
Markets mixed as traders struggle to hold Fed cut rally
-
Asian markets mixed as traders struggle to hold Fed cut rally
-
In Turkey, ancient carved faces shed new light on Neolithic society
-
Asian markets stumble as traders struggle to hold Fed cut rally
-
Nintendo launches long-awaited 'Metroid Prime 4' sci-fi blaster
-
Trump scraps Biden's fuel-economy standards, sparking climate outcry
-
US stocks rise as weak jobs data boosts rate cut odds
-
Poor hiring data points to US economic weakness
-
Germany to host 2029 women's Euros
-
Satellite surge threatens space telescopes, astronomers warn
-
Greek govt warns farmers not to escalate subsidy protest
-
EU agrees deal to ban Russian gas by end of 2027
-
Former king's memoirs hits bookstores in Spain
-
German lithium project moves ahead in boost for Europe's EV sector
-
Stock markets mostly rise awaiting US data
-
Norway postpones deep-sea mining activities for four years
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
J.Bondarev--CPN